-DOCSTART- -X- O
The -X- _ O
IFNL4 -X- _ O
gene -X- _ O
is -X- _ O
a -X- _ O
recently -X- _ O
discovered -X- _ O
type -X- _ O
III -X- _ O
interferon -X- _ O
, -X- _ O
which -X- _ O
in -X- _ O
a -X- _ O
significant -X- _ O
fraction -X- _ O
of -X- _ O
the -X- _ O
human -X- _ O
population -X- _ O
harbours -X- _ O
a -X- _ O
frameshift -X- _ O
mutation -X- _ O
abolishing -X- _ O
the -X- _ O
IFNλ4 -X- _ O
ORF. -X- _ O
The -X- _ O
expression -X- _ O
of -X- _ O
IFNλ4 -X- _ B-Intervention
is -X- _ O
correlated -X- _ O
with -X- _ O
both -X- _ O
poor -X- _ O
spontaneous -X- _ O
clearance -X- _ O
of -X- _ O
hepatitis -X- _ B-Patient
C -X- _ I-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
HCV -X- _ I-Patient
) -X- _ I-Patient
and -X- _ O
poor -X- _ O
response -X- _ O
to -X- _ O
treatment -X- _ O
with -X- _ O
type -X- _ O
I -X- _ O
interferon. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
the -X- _ O
IFNL4 -X- _ O
gene -X- _ O
encodes -X- _ O
an -X- _ O
active -X- _ O
type -X- _ O
III -X- _ O
interferon -X- _ O
, -X- _ O
named -X- _ O
IFNλ4 -X- _ O
, -X- _ O
which -X- _ O
signals -X- _ O
through -X- _ O
the -X- _ O
IFNλR1 -X- _ O
and -X- _ O
IL-10R2 -X- _ O
receptor -X- _ O
chains. -X- _ O
Recombinant -X- _ B-Outcome
IFNλ4 -X- _ I-Outcome
is -X- _ I-Outcome
antiviral -X- _ I-Outcome
against -X- _ I-Outcome
both -X- _ I-Outcome
HCV -X- _ I-Outcome
and -X- _ I-Outcome
coronaviruses -X- _ I-Outcome
at -X- _ I-Outcome
levels -X- _ I-Outcome
comparable -X- _ I-Outcome
to -X- _ I-Outcome
IFNλ3. -X- _ I-Outcome
However -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
secretion -X- _ I-Outcome
of -X- _ I-Outcome
IFNλ4 -X- _ I-Outcome
is -X- _ I-Outcome
impaired -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
that -X- _ I-Outcome
of -X- _ I-Outcome
IFNλ3 -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
this -X- _ I-Outcome
impairment -X- _ I-Outcome
is -X- _ I-Outcome
not -X- _ I-Outcome
due -X- _ I-Outcome
to -X- _ I-Outcome
a -X- _ I-Outcome
weak -X- _ I-Outcome
signal -X- _ I-Outcome
peptide -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
was -X- _ I-Outcome
previously -X- _ I-Outcome
believed. -X- _ I-Outcome
We -X- _ I-Outcome
found -X- _ I-Outcome
that -X- _ I-Outcome
IFNλ4 -X- _ I-Outcome
gets -X- _ I-Outcome
N-linked -X- _ I-Outcome
glycosylated -X- _ I-Outcome
and -X- _ I-Outcome
that -X- _ I-Outcome
this -X- _ I-Outcome
glycosylation -X- _ I-Outcome
is -X- _ I-Outcome
required -X- _ I-Outcome
for -X- _ I-Outcome
secretion. -X- _ I-Outcome
Nevertheless -X- _ I-Outcome
, -X- _ I-Outcome
this -X- _ I-Outcome
glycosylation -X- _ I-Outcome
is -X- _ I-Outcome
not -X- _ I-Outcome
required -X- _ I-Outcome
for -X- _ I-Outcome
activity. -X- _ I-Outcome
Together -X- _ O
, -X- _ O
these -X- _ O
findings -X- _ O
result -X- _ O
in -X- _ O
the -X- _ O
paradox -X- _ O
that -X- _ O
IFNλ4 -X- _ B-Outcome
is -X- _ I-Outcome
strongly -X- _ I-Outcome
antiviral -X- _ I-Outcome
but -X- _ I-Outcome
a -X- _ I-Outcome
disadvantage -X- _ I-Outcome
during -X- _ I-Outcome
HCV -X- _ I-Outcome
infection -X- _ I-Outcome
. -X- _ O

